Oncotarget

Research Papers:

New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer

Wei Yuan, Wanyan Tang, Yibin Xie, Shaoming Wang, Yingtai Chen, Jun Qi, Youlin Qiao and Jie Ma _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:80033-80045. https://doi.org/10.18632/oncotarget.12406

Metrics: PDF 745 views  |   HTML 1307 views  |   ?  


Abstract

Wei Yuan1,5,*, Wanyan Tang1,*, Yibin Xie2, Shaoming Wang3, Yingtai Chen2, Jun Qi4, Youlin Qiao3, Jie Ma1,5

1State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

2Department of Abdominal Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

3Department of Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

4Department of Clinical Laboratory, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

5Clinical Immunology Center, Chinese Academy of Medical Science, Beijing, 100730, China

*These authors have contributed equally to this work

Correspondence to:

Jie Ma, email: majie@cicams.ac.cn

Keywords: pancreatic cancer, plasma miRNAs, MIC-1, diagnosis, sensitivity and specificity

Received: May 26, 2016    Accepted: September 02, 2016    Published: October 03, 2016

ABSTRACT

Introduction: Lack of diagnostic makers results in loss of operation opportunity in that most patients are diagnosed at the late stage. Pancreatic cancer (PC) has been regarded as a fatal disease with a 5-year survival rate below 10%. Therefore, the development of diagnostic biomarkers for PC is in urgent need to control the mortality of the disease.

Materials and Methods: This is a case-control study including 640 plasma samples from healthy controls (HC), patients with benign pancreatic diseases (BPD), patients with PC; and patients with other gastrointestinal (GI) cancers. Eight biomarker candidates, including miR-20a, miR-21, miR-25, miR-155, miR-196a, miR-210, Macrophage Inhibitory Cytokine-1(MIC-1) and CA19-9, were evaluated to establish two diagnostic indexes in this study.

Results: The plasma level of the six miRNAs and MIC-1, CA19-9 were elevated in PC patients compared with those of healthy controls (P<0.001). Among them, miR-20a, miR-21, miR-25, MIC-1 and CA19-9 could distinguish PC patients from those with other GI cancers or BPD. With multivariable logistic regression, we established two specific indexes for diagnosis of PC(Index1 contains miR-21, MIC-1 and CA19-9; Index2 contains miR-25, MIC-1 and CA19-9). In a randomized setting of 260 HC, 168 PC, 132 other GI cancers and 80 BPD patients, both indexes performed not only better sensitivity for PC but also better specificity to distinguish PC from other GI cancers than CA19-9 and individual biomarkers.

Conclusions: These results indicated that combination of biomarkers as a panel could improve diagnostic values compared with using a single marker. Such panels as illustrated in this study could provide novel plasmatic biomarker for PC diagnosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12406